Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ARTL
- Price
- 0.82
- Stock movement down
- -0.00 (-0.02%)
- Company name
- Artelo Biosciences Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 2.65M
- Ent value
- -929.15K
- Price/Sales
- -
- Price/Book
- 0.42
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -31.15%
- 1 year return
- -47.88%
- 3 year return
- -50.44%
- 5 year return
- -43.31%
- 10 year return
- -
Last updated: 2025-04-11
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ARTL does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 0.42 |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 3.23M |
| EPS (TTM) | -2.83 |
| FCF per share (TTM) | -2.60 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -9.54M |
| Net income (TTM) | -9.12M |
| EPS (TTM) | -2.83 |
| EPS (1y forward) | -0.48 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 4.36M |
| Net receivables | 0.00 |
| Total current assets | 4.99M |
| Goodwill | 0.00 |
| Intangible assets | 2.04M |
| Property, plant and equipment | 108.00K |
| Total assets | 7.14M |
| Accounts payable | 627.00K |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 697.00K |
| Total liabilities | 775.00K |
| Shareholder's equity | 6.36M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -8.38M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -8.38M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -143.39% |
| Return on Assets | -127.82% |
| Return on Invested Capital | -143.39% |
| Cash Return on Invested Capital | -131.72% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.83 |
| Daily high | 0.89 |
| Daily low | 0.82 |
| Daily Volume | 50K |
| All-time high | 324.00 |
| 1y analyst estimate | 5.33 |
| Beta | 1.35 |
| EPS (TTM) | -2.83 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 12 May 2025 |
Downside potential
Loading...
Downside potential data
| ARTL | S&P500 | |
| Current price drop from All-time high | -99.75% | -12.89% |
| Highest price drop | -99.75% | -56.47% |
| Date of highest drop | 11 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -93.25% | -11.07% |
| Avg time to new high | 197 days | 12 days |
| Max time to new high | 1568 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
2.65M
Marketcap category
Small-cap
Description
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Employees
5
Website
Investor relations
-
SEC filings
CEO
Gregory D. Gorgas
Country
USA
City
San Diego
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page